英國媽媽率先採用突破性的T細胞療法治療多發性硬化症

Emily Henders, a biology teacher and mother of two from Bushey, Hertfordshire, has become the first person in the UK to receive a groundbreaking new treatment for multiple sclerosis, known as CAR T cell therapy. Multiple sclerosis, or MS, is an autoimmune disease that affects the brain and spinal cord, causing symptoms like weakness, fatigue, and difficulty walking. Emily was diagnosed with MS in December 2021, and since then, she has experienced frightening relapses where her legs stop working and she cannot walk. These episodes have been tough for her and her family, especially her young children. The new treatment Emily is trying is called CAR T cell therapy, which has already shown success in treating blood cancer. The therapy works by genetically modifying a patient's own T cells, which are part of the immune system, to target and reset the immune system. In MS, the immune system mistakenly attacks healthy cells in the brain and spinal cord. By using CAR T cell therapy, doctors hope to stop or slow down the progression of MS and prevent further relapses. Emily received the treatment as part of a global clinical trial, which aims to recruit up to 18 patients by early 2027. After the three-minute infusion, Emily reported feeling well, with no nausea or fever, and her energy had returned. She hopes that participating in the trial will mean she never has to experience another relapse and that her MS symptoms will not get worse. As a biology teacher, she understands the science behind the treatment and feels hopeful about its potential. Emily and her husband Brandon would like to have a third child, but they are concerned about how her MS might affect their family. Emily's father also has MS, so she knows firsthand how challenging the disease can be. She remembers her first major relapse, when she was unable to stand and had to be taken to the hospital by ambulance in front of her children. This experience was traumatic for her and her family, and she worries about the emotional impact on her children and the possibility of passing MS on to them. Emily is one of 150,000 people in the UK living with MS. She hopes that the new treatment will help her avoid the decline that many MS patients face, such as needing a wheelchair. Being able to stay active and continue working as a science teacher is important to her, as using a wheelchair or crutches would make her job difficult and could even be a safety hazard. The MS Society has expressed optimism about the trial, saying that if CAR T cell therapy proves successful, it could revolutionize the way MS is treated. Dr. Claire Roddie, a consultant haematologist involved in the trial, said the team is excited to repurpose a treatment originally developed for cancer to help people with MS. She explained that the goal is for patients to receive the therapy and hopefully not need any more drugs afterward. If this can be achieved, it would transform the lives of many people living with MS.

Emily's participation in the trial is a sign of hope for others with MS. Her story highlights the importance of medical research and the potential for new treatments to improve the lives of people with chronic illnesses. The support of her family and the dedication of doctors and scientists are helping to push the boundaries of what is possible in MS treatment.

As the trial continues, many people are watching to see if CAR T cell therapy will become a new standard for treating MS. If successful, it could offer a better future for thousands of people in the UK and around the world who are living with this challenging disease.